https://pf04217903inhibitor.co....m/willinfrmd6-impact
METHODS The performance of the Roche cobas 4800 platform ended up being assessed in the FNA material from the cellular pellet and corresponding cell-free supernatant substance specimens of main and metastatic HNSCCs. These outcomes were compared with the p16 immunostain result from the histologic material obtained from the same patient. Discrepant situations were adjudicated making use of hrHPV RNA in situ hybridization. OUTCOMES an overall total of 41 exa
Like
Comment
Share
